Azitra, Inc.
AZTR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AZTR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AZTR
Azitra, Inc. (AZTR) is a clinical-stage precision dermatology company developing engineered proteins and topical live biotherapeutic products, with lead programs ATR-12 (Netherton syndrome) and ATR-04 (EGFRi-associated rash) in Phase 1b/2a trials.
Key risk: Limited cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Azitra, Inc..
Azitra, Inc. (AZTR) is a clinical-stage precision dermatology company developing engineered proteins and topical live biotherapeutic products, with lead programs ATR-12 (Netherton syndrome) and ATR-04 (EGFRi-associated rash) in Phase 1b/2a trials.
- Azitra is focused on precision dermatology using engineered proteins and topical live biotherapeutic products, with a proprietary microbial library of approximately 1,500 unique bacterial strains [sec_mda · as of 2024-11-12].
- Lead program ATR-12 received FDA clearance to proceed with a Phase 1b trial in Netherton syndrome patients in January 2023; dosing began in August 2024 [sec_mda · as of 2025-02-24].
- ATR-04 received FDA IND clearance for a Phase 1b/2a trial in patients with EGFRi-associated rash in August 2024, and was granted Fast Track designation in September 2024 [sec_mda · as of 2025-02-24].
- As of June 30, 2026, Azitra reported cash and equivalents of $6.7 million, shareholders' equity of $3.8 million, and a net loss of $3.3 million for the period [sec].
- The company is under a NYSE American compliance plan through April 1, 2027, to regain compliance with continued listing standards [sec_mda · as of 2026-02-27].
What works
- Azitra has two clinical-stage programs (ATR-12 and ATR-04) that have received FDA clearance to proceed and Fast Track designation, indicating regulatory support for their development [sec_mda · as of 2025-02-24].
- The company's proprietary platform includes a library of ~1,500 unique bacterial strains and pending patent applications, providing a foundation for a pipeline of product candidates [sec_mda · as of 2024-11-12].
- Azitra has a collaboration with Bayer and is exploring strategic partnerships to expand its precision dermatology platform [sec_mda · as of 2024-11-12].
What to weigh
- Azitra has no revenue-generating operations and has incurred net losses, with a net loss of $3.3 million for the six months ended June 30, 2026 [sec].
- The company faces a going-concern risk due to limited cash ($6.7 million as of June 30, 2026) and the need to raise additional capital to fund operations and clinical trials [sec_mda · as of 2025-11-12].
- Azitra is at risk of delisting from NYSE American if it fails to meet continued listing standards by the April 1, 2027 deadline under its compliance plan [sec_mda · as of 2026-02-27].
- The company has a limited operating history and has not yet commercialized any product, with all programs in early clinical or preclinical stages [sec_mda · as of 2025-11-12].
From the filings
Quoted directly from source documents.
Azitra's lead programs ATR-12 and ATR-04 are in clinical trials.
“Advance our lead programs, ATR-12 and ATR-04, through clinical trials. In 2022, we obtained pre-IND correspondence with the FDA for purposes of discussing our proposed regulatory pathway for the ATR-12 program and obtaining guidance from the FDA on the preclinical plan leading to the filing and acceptance of an IND for ATR-12.”
SEC MD&A · November 12, 2025
Azitra has a proprietary microbial library of approximately 1,500 unique bacterial strains.
“We intend to create a broad portfolio of product candidates for precision dermatology through our development of genetically engineered proteins selected from our proprietary microbial library of approximately 1,500 unique bacterial strains.”
SEC MD&A · November 12, 2024
Azitra is under a NYSE American compliance plan with a deadline of April 1, 2027.
“Plan and granted a plan period through April 1, 2027 (the "Plan Period Deadline"). The Company will be able to continue its listing during the plan period and will be subject to continued periodic review by the NYSE American staff.”
SEC MD&A · February 27, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $6.7M as of June 30, 2026 may not be sufficient to fund operations and clinical trials without additional financing [sec].
- NYSE American delisting risk — Company must meet continued listing standards by April 1, 2027 or face delisting [sec_mda · as of 2026-02-27].
- No approved products or revenue — Azitra has no commercial products and relies on future regulatory approvals and market acceptance [sec_mda · as of 2025-11-12].
- Early-stage clinical programs — Both lead programs are in Phase 1b/2a trials; clinical data and regulatory outcomes are uncertain [sec_mda · as of 2025-02-24].
What to watch
- Progress of ATR-12 Phase 1b trial in Netherton syndrome and ATR-04 Phase 1b/2a trial in EGFRi-associated rash [sec_mda · as of 2025-02-24].
- Ability to raise additional capital to extend cash runway beyond $6.7 million [sec].
- Compliance with NYSE American listing standards by the April 1, 2027 deadline [sec_mda · as of 2026-02-27].
- Any strategic partnership or licensing deals that could provide non-dilutive funding or accelerate development [sec_mda · as of 2025-11-12].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Azitra, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Azitra, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
6.3 months
D/E 0.22 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$116K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 469,878 | $110K |
| stonex group inc. | 22,464 | $5K |
| citigroup inc | 1,705 | $399 |
| fmr llc | 150 | $35 |
Short Interest
as of May 20, 2026- % of float
- 2.5%
- Days to cover
- 0.5
- Shares short
- 397,818
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AZTR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Azitra, Inc.?
Azitra, Inc. (AZTR) is a clinical-stage precision dermatology company developing engineered proteins and topical live biotherapeutic products, with lead programs ATR-12 (Netherton syndrome) and ATR-04 (EGFRi-associated rash) in Phase 1b/2a trials.
Who is the CEO of Azitra, Inc.?
Mr. Francisco D. Salva is the chief executive officer of Azitra, Inc. (AZTR).
Where is Azitra, Inc. headquartered?
Azitra, Inc. (AZTR) is headquartered in Branford, CT, United States.
What therapeutic areas does Azitra, Inc. focus on?
Azitra, Inc. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.